DiaMedica Therapeutics Inc. (DMAC:NASDAQ) closed at $8.04 on October 15, 2026, up 4.96% on the day. The stock trades 22.8% below its 52-week high of $10.42 and 53.3% above its 52-week low of $5.25. Over the past year, it gained 20.4%. DiaMedica Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -1.95% | +21.27% | +14.69% | +22.56% | +20.36% |
In 252 trading sessions since October 15, 2025, DMAC closed higher on 117 days (46%). Its best day was November 25, 2025 (+12.88%) and its worst was November 13, 2025 (-14.10%). The stock moved 10% or more in a single session 4 times.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. It is principally engaged in the business activity of developing treatments for unmet clinical need or where no therapies are available with a primary focus on neurological and kidney diseases. Its pipeline products include DM300, DM199, and others. Majority of the company's operations are carried out in the United States of America.
Find more stocks like DMAC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.